The most interesting and notable breast and ovarian cancer research from the 2010 ASCO (American Society of Clinical Oncology) conference.
Held in Chicago June 4-8, the annual meeting brought together 50,000 physicians, researchers, and other health care professionals from around the globe to discuss and hear the latest results in cancer research. Click the links to read the articles on the ASCO website.
For patients receiving neoadjuvant therapy for breast cancer, both treatment dose and duration affect the likelihood of attaining a pathologic complete response (pCR), according to results of a pooled multi-layer retrospective analysis presented by Gunter Von Minckwitz, MD, PhD, of Universitäts-Frauenklinik Frankfurt, Germany, and the German Breast Group, during Sunday’s Clinical Science Symposium: “Predictors of Response to Preoperative Therapy: Where Are We?”
New data indicate that axillary lymph node dissection is not necessary for women with clinically node-negative breast cancer who undergo sentinel node biopsy. In addition, immunohistochemistry (IHC) provides no additional benefit for patients with clinically node-negative disease and histologically negative nodes.
A phase II translational study of olaparib, an orally active poly (ADP-ribose) polymerase (PARP) inhibitor, showed promising results for women with high-grade serous ovarian cancer regardless of BRCA mutation status